Mirae Asset Venture Investment Finalizes Consecutive IPO Schedules for Second Half... "Recovery Clock Starts"

Expectations for strong earnings in the second half of the year are rising rapidly as the initial public offering schedules for key portfolio companies held by Mirae Asset Venture Investment have been consecutively confirmed for November and December.

Starting with CMTX and Terraview in November, followed by Livesmed and Semifive in December, the subscription schedules have been firmly set, making it likely that Mirae Asset Venture Investment will be able to recognize significant valuation and disposal gains in the second half of the year. The main portfolio companies’ public subscription schedules are as follows: CMTX on November 10-11, Terraview on November 24-25, Livesmed on December 1-2, and Semifive on December 2-3.

Additionally, Proteina, a biotech company that was listed on KOSDAQ in July, is being cited as an extra momentum driver. Proteina was established based on the technology of Professor Yoon Taeyoung from Seoul National University’s Department of Biological Sciences and possesses a core platform capable of quantifying protein-protein interactions (PPI) at the single-molecule level. This technology is applied to the “PPI PathFinder,” which discovers biomarkers, and the “PPI Landscape,” which builds big data on antigen-antibody interactions for use in drug and antibody design.

In particular, as the possibility grows that this technology could be applied to companion diagnostics and efficacy monitoring for innovative new drug pipelines held by global pharmaceutical companies such as AbbVie, the market is highlighting the future upside potential. Furthermore, given its ability to produce high-quality PPI data on a large scale, Proteina is expected to play a key role in the government’s ongoing project to establish a cloud-based AI antibody bank.

The share price of Proteina has risen to more than four times its IPO price of 14,000 won, and the market sentiment remains open to the possibility of further significant upside. As Mirae Asset Venture Investment is known to have not yet sold a substantial portion of its holdings in Proteina, the company is emerging as a major asset for recovery that will drive earnings improvement in the second half of the year, alongside newly listed portfolio companies in the fourth quarter.

This content was produced with the assistance of AI translation services.